ArticleHuman molecular genetics2026
Individuals with reported and novel KDM5C variants present with seizures, a feature recapitulated in a Drosophila model.
Article in Human molecular genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
4 authors.
Funding
Abstract
Variants that disrupt the function of the chromatin regulator KDM5C cause a rare neurodevelopmental disorder (KDM5C-NDD) characterized by intellectual disability, seizures, and a broad range of systemic features. To better understand this disorder, more detailed and standardized information is required regarding the association between these genetic variants and cognitive and behavioral traits. Utilizing data obtained by the RARE-X KDM5C Data Collection Program, we analyzed survey and genetic data from 31 newly reported individuals. In addition to the expected neurodevelopmental challenges, participants frequently reported growth abnormalities, vision and digestive issues, behavioral concerns, and seizures in nearly half of the cases. Meta-analyses of this data and previously published cases reaffirmed that seizures are a frequent feature in both hemizygous males and heterozygous females with KDM5C variants, with over a third of individuals reporting at least one seizure. Based on the prevalence of seizures in the RARE-X and published datasets, we sought to develop robust quantitative assays of KDM5-associated seizure behavior using the model organism Drosophila. Reducing the expression of its single Kdm5 gene in neurons, but not glia, led to spontaneous and stimulus-induced seizures, underscoring a cell-intrinsic requirement for KDM5 in maintaining neuronal stability. Together, these human and fly studies highlight KDM5C as a critical regulator of nervous system function, demonstrating how patient-driven data collection and scalable model systems can be effectively integrated. This work expands our understanding of KDM5C-NDD and lays the groundwork for future therapeutic discoveries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.